Zacks Investment Research Upgrades Shire PLC (SHPG) to "Hold"


According to Zacks, "Shire's third-quarter results were impressive with the company beating on both top- and bottom-line estimates. It holds a strong position in the ADHD market driven by Vyvanse.



from Biotech News